CRAD B C-RAD AB

Leave to Appeal in patent dispute over C-RAD’s entitlement to patents granted

Leave to Appeal in patent dispute over C-RAD’s entitlement to patents granted

The Stockholm Patent and Market court confirmed in its verdict dated July 26, 2019, C‑RAD’s right to the patent application “Ionizing radiation detecting device”. The

opposing party, Beamocular AB, appealed the verdict. Now, the appeal court (Svea Hovrätt- Patent- och marknadsöverdomstolen) has granted leave to appeal.

Leave to appeal is granted in the large majority of appeals in patent cases. The decision to leave grant to the appeal does in itself not indicate how the appeal court will rule after having heard the case on the merits.

The appeal court will try the case based on the same material as in the district court. C‑RAD’s view is that nothing new has happened, and C-RAD’s assessment of its chances to successfully defend its right to the invention remains unchanged.

Background

The background to the dispute relates to a patent entitlement lawsuit that C-RAD filed against Beamocular with the Patent and Market Court in Stockholm on May 22, 2017. C-RAD claims the ownership rights of the invention described in the patent application “Ionizing radiation detecting device” from Beamocular. The ownership in the rights of the patent does not have a significant impact on C‑RADs long-term strategy as the patent is not utilized at the moment.

For further information:

Tim Thurn, CEO C-RAD AB, Phone , Email

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit -rad.com

Attachment

EN
03/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C-RAD AB

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Erik Cassel
  • Erik Cassel

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

Erik Cassel
  • Erik Cassel

Sector Fast Comment - Hospital data update

Better hospital margins in August Congress passed supportive spending bill Small positive for companies with capex exposure

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Record heat on orders beat

Remarkable order intake 35% better than ABGSCe ‘23e EBIT up 8% and ‘24e up 4% Fair value range of SEK 45-95/share

ResearchPool Subscriptions

Get the most out of your insights

Get in touch